The Global Nonalcoholic Steatohepatitis Treatment Market, By Drug (Cenicriviroc, Elafibranor, Ocaliva, and Selonsertib), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 1,119.8 million in 2017 (based on existing approved therapies including anti-diabetics, vitamins, dietary supplements, and others) and is projected to exhibit a CAGR of 42.7% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.
Nonalcoholic fatty liver disease (NAFLD) is a condition which occur due to the presence of fat in more than 5% of liver cells. NAFLD affects people who consume little or no alcohol. According to the Harvard Medical School, January 2018 report, NAFLD is the most common liver disease and affects nearly 25% of American adults, 60% of whom were men. It increases the risk of heart disease and if left untreated, it can lead to nonalcoholic steatohepatitis (NASH), a condition causing inflamed liver. More than 40% of people with NAFLD develop NASH which can lead to scarring of the liver. Severe liver scarring, known as cirrhosis, increases the risk of liver cancer.
Get Sample PDF of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2279
The most widely used treatment for NASH is to eliminate potential causes and risk factors such as weight loss and treatment for hyperglycemia or dyslipidemia. A study published by the National Center for Biotechnology Information in 2015, suggests that thiazolidinediones and vitamin E can help correct biochemical and histologic abnormalities in NASH.
Moreover, no medicines have been approved to treat NASH so far. However, researchers are developing medicines to improve the conditions. According to the National Institute of Diabetes and Digestive and Kidney Diseases, some studies suggest that pioglitazone (Actos), a medicine for type 2 diabetes, can improve NASH in people non-diabetic patients.
Companies in the market are focusing on extensive research to develop medicine for NASH treatment. For instance, in 2017, Gilead Sciences, Inc. announced results from a Phase 2, randomized, placebo-controlled trial evaluating two doses of GS-0976, an oral, investigational inhibitor of Acetyl-CoA carboxylase, in patients with nonalcoholic steatohepatitis.
Browse 26 Market Data Tables and 28 Figures spread through 187 Pages and in-depth TOC on “Nonalcoholic Steatohepatitis Treatment Market, By Drug (Cenicriviroc, Elafibranor, Ocaliva, and Selonsertib), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2026”
To know the latest trends and insights related to nonalcoholic steatohepatitis treatment market, click the link below:
Key Takeaways of the Nonalcoholic Steatohepatitis Treatment Market:
- The global nonalcoholic steatohepatitis treatment market is expected to expand at a CAGR of 42.7% during the forecast period (2018–2026), owing to increasing incidences of nonalcoholic fatty liver disease. According to the State of Obesity data, in 2016, approximately 100 million individuals in the U.S were suffering from have nonalcoholic fatty liver disease.
- Among region, Asia Pacific is expected to grow at highest rate owing to increasing population with diabetes owing to the rising prevalence of diabetes driven by a combination of factors including sedentary lifestyles, rapid urbanization, and unhealthy diets. According to the WHO, diabetes is a growing challenge in India with estimated 8.7% diabetic population in the age group of 20 and 70 years.
- Major players operating in the global nonalcoholic steatohepatitis treatment market include AstraZeneca Plc., Conatus Pharmaceuticals, Enzo Biochem, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Gilead Science, Immuron Ltd., Intercepts Pharmaceuticals, Novo Nordisk, Raptor Pharmaceutical Corporation, and Tobira Therapeutics, Inc.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Company Name: Coherent Market Insights
Contact Person: Mr. Shah
Email: Send Email
Address:1001 4th Ave, #3200
Country: United States